Talecris Biotherapeutics has launched its ice-breaking IPO, saying it will sell 44.7 million shares at $18 to $20 per share. Analysts say the life sciences offering is solid proof that the once frozen market has begun to thaw and the Research Triangle Park-based company is leading the way. Release [1]| Report [2]
Links:
[1] http://www.fiercebiotech.com/press-releases/talecris-commences-initial-public-offering-common-stock
[2] http://www.ft.com/cms/s/0/38407116-a151-11de-a88d-00144feabdc0.html